Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Endostar in High-Risk Locally Advanced Nasopharyngeal Carcinoma
NCT04447326Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jun 2020
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of toripalimab, endostar in nasopharyngeal carcinoma (NPC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
toripalimabendostar
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04447326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447326.